WO1993024629A1 - Cellule exprimant un recepteur de glutamate - Google Patents
Cellule exprimant un recepteur de glutamate Download PDFInfo
- Publication number
- WO1993024629A1 WO1993024629A1 PCT/DK1993/000169 DK9300169W WO9324629A1 WO 1993024629 A1 WO1993024629 A1 WO 1993024629A1 DK 9300169 W DK9300169 W DK 9300169W WO 9324629 A1 WO9324629 A1 WO 9324629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- glutamate
- receptor
- glutamate receptor
- dna sequence
- Prior art date
Links
- 102000018899 Glutamate Receptors Human genes 0.000 title claims abstract description 53
- 108010027915 Glutamate Receptors Proteins 0.000 title claims abstract description 53
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 29
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 28
- 239000012634 fragment Substances 0.000 claims abstract description 20
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 8
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 107
- 238000000034 method Methods 0.000 claims description 35
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 29
- 229930195712 glutamate Natural products 0.000 claims description 27
- 102000005962 receptors Human genes 0.000 claims description 27
- 108020003175 receptors Proteins 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 24
- 239000003446 ligand Substances 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 13
- 238000012216 screening Methods 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 10
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 claims description 7
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 229940024606 amino acid Drugs 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 230000004907 flux Effects 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 210000003292 kidney cell Anatomy 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims 2
- RPXVIAFEQBNEAX-UHFFFAOYSA-N 6-Cyano-7-nitroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(C#N)=C2 RPXVIAFEQBNEAX-UHFFFAOYSA-N 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 21
- 239000013598 vector Substances 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 238000001890 transfection Methods 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 101150111020 GLUL gene Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000003823 glutamate receptor agonist Substances 0.000 description 2
- 239000003825 glutamate receptor antagonist Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- LZHKSYSAYWIFSU-QCZKYFFMSA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxy-2-nitro-1-phenylhexan-1-one Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@](O)([N+]([O-])=O)C(=O)C1=CC=CC=C1 LZHKSYSAYWIFSU-QCZKYFFMSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- JTNGEYANGCBZLK-UHFFFAOYSA-N 1h-indol-3-yl dihydrogen phosphate Chemical compound C1=CC=C2C(OP(O)(=O)O)=CNC2=C1 JTNGEYANGCBZLK-UHFFFAOYSA-N 0.000 description 1
- IAWXTSMHXFRLQR-UHFFFAOYSA-N 2,3-bis($l^{1}-oxidanyl)-7-nitroquinoxaline-6-carbonitrile Chemical compound O=C1C(=O)N=C2C=C(C#N)C([N+](=O)[O-])=CC2=N1 IAWXTSMHXFRLQR-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 102000006941 Amino Acid Transport System X-AG Human genes 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 229940117892 Glutamate receptor agonist Drugs 0.000 description 1
- 108091006151 Glutamate transporters Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 108091034131 VA RNA Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- -1 amino acids glutamate Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001253 anti-conflict Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- UGJCNRLBGKEGEH-UHFFFAOYSA-N sodium-binding benzofuran isophthalate Chemical compound COC1=CC=2C=C(C=3C(=CC(=CC=3)C(O)=O)C(O)=O)OC=2C=C1N(CCOCC1)CCOCCOCCN1C(C(=CC=1C=2)OC)=CC=1OC=2C1=CC=C(C(O)=O)C=C1C(O)=O UGJCNRLBGKEGEH-UHFFFAOYSA-N 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Definitions
- the present invention relates to mammalian cells capable of stably expressing glutamate receptors, as well as to a method of screening for substances interacting with glutamate receptors by means of said cell.
- glutamate receptor subunits have recently been prepared by recombinant DNA techniques. The cloning of DNA coding for glutamate receptor subunits and expression thereof in Xenopus oocytes is described in WO 91/06648. Transient expression of four glutamate receptor subunits in human embryonic kidney cells is reported by T.A. Verdoorn et al., Neuron 4_, 1990, p. 919, and Keinanen et al., Science 249, 1990, pp. 556-560. However, no cells stably expressing glutamate receptors have previously been reported. SUMMARY OF THE INVENTION
- the present invention relates to a mammalian cell transfected with a DNA sequence encoding a protein with electrophysiological and pharmacological properties characteristic of a glutamate receptor, or a functional fragment of said protein, and capable of permanently expressing said DNA sequence.
- glutamate receptor refers to a membrane component present on neurons and certain other cells and activated by glutamate.
- glutamate receptor is intended to indicate a protein which generates a signal or signals comparable to the signal or signals generated by native glutamate receptors when activated in the presence of glutamate, and which can be affected by substances known to affect native glutamate receptors.
- the protein is usually referred to as a glutamate receptor-like protein or a GluR-like protein.
- the term "functional fragment” is intended to indicate a fragment with properties corresponding to those of a glutamate receptor.
- the cells of the present invention are distinguished from those described in T.A. Verdoorn et al., supra. or Keinanen et al, supra. by being capable of stably expressing glutamate receptor-like proteins. This is an important advantage when such cells are to be used to screen for substances interacting with the receptors as stable cell lines are less expensive to produce and more convenient to use because no large-scale production RNA or DNA is required for transfection of cells.
- Cells capable of permanently expressing glutamate-receptor-like proteins have been found to express a membrane component which is able to bind glutamate with high affinity but which has a different pharmacology from any known glutamate receptor in that it is not activated by glutamate.
- this component believed to be a glutamate transporter, i.e. a protein transporting glutamate from the exterior to the interior of the cell, causes less free glutamate, which is a common constituent in cell culture media, to be present in the vicinity of the cells. Consequently less excitation of the glutamate receptors expressed on the surface of the cells, eventually resulting in cell death, will occur (continuous stimulation of glutamate receptors has been reported to be the major cause of cell death in ischaemia, cf. D.W. Choi, Neuron 1 , 1988, pp. 623- 634).
- the present invention relates to a method of screening for a substance capable of interacting with a glutamate receptor, the method comprising incubating a cell according to the invention with a sample suspected of containing a substance capable of interacting with a glutamate receptor or with an agonist of a glutamate receptor, and detecting any interaction of said substance with a protein with electrophysiological and pharmacological properties characteristic of a glutamate receptor, or a functional fragment of said protein, the protein or fragment being present on said cell, or detecting any interaction of said substance with said agonist.
- the term "interacting with” is intended to include substances which are able to bind to a glutamate receptor or a possible associated protein, thereby either stimulating the receptor or blocking agonist effects on the receptor, or which otherwise allosterically affect receptor function.
- the DNA sequence encoding the glutamate receptor-like protein introduced into the cell of the invention may be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by S.L. Beaucage and M.H. Caruthers, Tetrahedron Letters 22. 1981, pp. 1859-1869, or the method described by Matthes et al., EMBO Journal 3. 1984, pp. 801-805.
- oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.
- the DNA sequence may also be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the GluR-like protein by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (cf. Sambrook et al.. Molecular Cloning: A Laboratory Manual. 2nd Ed. , Cold Spring Harbor, 1989) .
- the DNA sequence may be obtained by procedures described in WO 91/06648.
- the DNA sequence may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by annealing fragments of synthetic, genomic or cDNA origin (as appropriate) , the fragments corresponding to various parts of the entire DNA sequence, in accordance with standard techniques.
- the DNA sequence may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202, or Saiki et al., Science 239. 1988, pp. 487-491.
- the resulting DNA sequence may be introduced into the cell by transfection of the cell with a recombinant expression vector comprising the sequence.
- the expression vector may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
- the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
- the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
- the DNA sequence encoding the GluR-like protein should be operably connected to a suitable promoter sequence.
- the promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.
- suitable promoters for directing the transcription of the DNA insert in mammalian cells are the SV 40 promoter (Subramani et al., Mol. Cell Biol. jL, 1981, pp. 854-864) , the MT-1 (metallothionein gene) promoter (Palmiter et al.. Science 222. 1983, pp. 809-814) or the adenovirus 2 major late promoter.
- the DNA sequence should also be operably connected to a suitable terminator, such as the human growth hormone terminator (Palmiter et al., op. cit.) .
- the vector may further comprise elements such as polyadenylation signals (e.g. from SV 40 or the adenovirus 5 Elb region) , transcriptional enhancer sequences (e.g. the SV 40 enhancer) and translational enhancer sequences (e.g. the ones encoding adenovirus VA RNAs) .
- the recombinant expression vector may also comprise a DNA sequence enabling the vector to replicate in the host cell in question.
- An examples of such a sequence is the SV 40 origin of replication.
- the vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or one which confers resistance to a drug, e.g. neomycin, hygromycin or methotrexate.
- DHFR dihydrofolate reductase
- a preferred cell for the for transfection with the expression vector containing the DNA sequence described above is one which, although it does not in nature express glutamate receptors, comprises endogenous transport systems capable of transporting glutamate or related amino acids to the interior of the cell.
- Examples of cells which are suitable for the present purpose are kidney cells, in particular those expressing a glutamate binding site other than the glutamate receptor, as described above, such as a baby hamster kidney (BHK) cell line (ATCC CRL 1632, ATCC CCL 10), the related BHK 570 cell line (ATCC CRL 6282 and ATCC CRL 10314 (described in WO 91/11514)) being particularly preferred.
- the DNA sequence encoding the GluR-like protein may, for instance, encode a glutamate receptor of the N-methyl-D- aspartate (NMDA) or the non-N-methyl-D-aspartate (non-NMDA) type. Both NMDA and non-NMDA receptors are defined in T. Honore, supra. More preferably, the DNA sequence may encode an ionotropic glutamate receptor, by which is meant a receptor forming ion channels in the membrane of cells expressing the receptor so as to make the membrane permeable to ions in response to agonist exposure, whereby an electrical signal is generated and the cells are depolarized; see i.a. M. Hollmann et al.. Science 252, 1991, pp.
- ionotropic glutamate receptors are Glul-4 flip and flop (cf. Sommer et al., Science 249, 1990, pp. 1580-1585), otherwise known as ⁇ - amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, Glu 5-7 (WO 91/06648) , or kainate 1 or 2 or ⁇ -2 receptors, or a functional fragment of any of these receptors, or a combination of two or more of said receptors or functional fragments thereof.
- AMPA ⁇ - amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
- the cell is a BHK 570 cell comprising a DNA sequence encoding an ionotropic glutamate receptor or a functional fragment thereof, or a combination of two or more ionotropic glutamate receptors or functional fragments thereof.
- the cells may be separated from the medium in which they are cultured to express the GluR-like receptor by any conventional method such as filtration or centrifugation and subsequently incubated with the sample.
- Suitable samples may be obtained from any material of biological origin, preferably in fluid form, e.g. a microbial fermentation broth, a plant or part(s) thereof, a tissue extract or solutions or suspensions of synthetic compunds of potential interest.
- the invention relates to a method of screening for an antagonist of ligand binding to the receptor, wherein the cell of the invention is incubated with a sample suspected of containing such an antagonist in the presence of a labelled ligand for the receptor.
- the invention relates to a method of screening for a substance interacting with glutamate receptor function via a binding site different from the glutamate receptor, i.e. a substance which is an allosteric modulator.
- the cell of the invention is incubated with a sample suspected of containing such a substance in the presence of an agonist followed by determination of any effect of said substance by detection methods such as those indicated below.
- the label substance with which the ligand is labelled is preferably selected from the group consisting of enzymes, coloured or fluorescent substances, or radioactive isotopes.
- enzymes useful as label substances are peroxidases (such as horseradish peroxidase) , phosphatases (such as acid or alkaline phosphatase) , ⁇ -galactosidase, urease, glucose oxidase, carbonic anhydrase, acetylcholinesterase, glu- coamylase, lysozyme, malate dehydrogenase, glucose-6-phosphate dehydrogenase, ⁇ -glucosidase, proteases, pyruvate de- carboxylase, esterases, luciferase, etc.
- peroxidases such as horseradish peroxidase
- phosphatases such as acid or alkaline phosphatase
- ⁇ -galactosidase urease, glucose oxidase, carbonic anhydrase, acetylcholinesterase, glu- coamylase, lysozyme, malate dehydrogen
- Enzymes are not in themselves detectable but must be combined with a substrate to catalyse a reaction the end product of which is detectable.
- substrates which may be em ⁇ ployed in the method according to the invention include hydrogen peroxide/tetramethylbenzidine or chloronaphthole or o-phenylenediamine or 3-(p-hydroxyphenyl) propionic acid or luminol, indoxyl phosphate, p-nitrophenylphosphate, nitro- phenyl galactose, 4-methyl umbelliferyl-D-galactopyranoside, or luciferin.
- the label substance may comprise coloured or fluorescent substances, including gold particles, coloured or fluorescent latex particles, dye particles, fluorescein, phycoerythrin or phycocyanin.
- the ligand is labelled with a radioactive isotope.
- Radioactive isotopes which may be used for the present purpose may be selected from 1-125, I- 131, In-Ill, H-3, P-32, C-14 or S-35. The radioactivity emitted by these isotopes may be measured in a beta- or gamma- counter or by a scintillation camera in a manner known per se.
- the labelled ligand may suitably be a glutamate receptor agonist or antagonist binding to the receptor.
- glutamate ⁇ -amino-3-hydroxy- 5-methyl-4-isoxazole propionic acid (AMPA) , 6-cyano-7- nitroquinoxaline-2,3-dion (CNQX) or kainate (kainic acid).
- AMPA ⁇ -amino-3-hydroxy- 5-methyl-4-isoxazole propionic acid
- CNQX 6-cyano-7- nitroquinoxaline-2,3-dion
- kainate kainic acid
- the method of the invention may be used to screen for a negative or positive modulator of glutamate receptor function, wherein said cell is incubated with a sample suspected of containing such a modulator in the presence of an agonist of the receptor, and wherein interaction of said substance with the glutamate receptor-like protein expressed by the cell is detected by measuring the ion flux across the cell membrane.
- the calcium or sodium may be measured, since glutamate receptors are selective for these two cations (cf. Hume et al., Science 253. 1991, pp. 1028-1031).
- a convenient technique comprises monitoring changes in the membrane potential of the cell by means of whole cell clamping, e.g. as described in Voltage and Patch Clamping with Microelectrodes. T.G. Smith et al. (Eds.), American Physiological Society, Maryland, USA, 1985.
- Another suitable technique comprises isolating membranes of cells according to the invention, and monitoring changes in the membrane potential on such isolated membranes incorporated in an artificial bilayer, e.g. as described in Ion Channel Reconstitution, CM. Miller (Ed.), Plenum Press, New York, 1986.
- a further suitable technique might be to monitor changes in intracellular concentrations of sodium, potassium or calcium ions by means of fluorescent probes, e.g. SBFI (S- 1264) or Fura (F-1225) , respectively (available from Molecular Probes) , followed by detection in a fluorospectrophotometer.
- fluorescent probes e.g. SBFI (S- 1264) or Fura (F-1225) , respectively (available from Molecular Probes) , followed by detection in a fluorospectrophotometer.
- Fig. 1 shows the presence of ionic conductances activated by glutamic acid or analogues thereof in BHK 570 cells expressing glutamate receptor cDNAs
- Fig. 2 shows a glutamate dose-response curve in a BHK 570 cell line expressing a glutamate receptor.
- BHK 570 cells (ATCC CRL 10314, described in WO 91/11514) were grown to 80-90% confluence in 24-well microtiter plates (Nunc
- DMEM Dulbecco's Modified Eagle's Medium
- the cells were then washed twice in ice-cold DMEM and lysed by adding 200 ⁇ l/well of 0.1 M NaOH. An aliquot of the lysed cells was counted in a beta counter for diffusion of 3 H- glutamate into the cells, and another aliquot was used for protein determination.
- Non-carrier mediated diffusion of glutamate into the cells was defined as uptake of 3 H-glutamate by the cells when incubating at 0°C.
- Cells found to have an endogenous transport system for glutamate and related amino acids (e.g. aspartate) were found to be capable of expressing glutamate receptors.
- 3 H-glutamate binding was carried as by the method described in Example 6 below for 3 H-AMPA binding.
- BHK 570 cells were found to express large quantities (30-50 pmole/mg membrane protein) of a putative membrane component which binds glutamate with high affinity (30-50 nM at 37°C). This binding site has a pharmacology differing from that of glutamate receptors (e.g. IC 50 (quisqualate) > 10 ⁇ M) . The presence of this putative membrane component is believed to be important for the ability of a cell stably to express glutamate receptors. BHK 570 is therefore the currently preferred cell for the present purpose.
- Total RNA was prepared from rat hippocampus or cerebellum by the acidic phenol method described by P. Chomczynski and N. Sacchi, Anal. Biochem. 162. 1987, pp. 156-159.
- First strand cDNA was prepared from 10 ⁇ g total rat brain RNA using oligo- dT primer and SuperscriptTM RNase H-reverse transcriptase as recommended by the manufacturer (BRL, Life Technologies) .
- PCR Polymerase chain reactions
- Glul TTAGGATCCACCATGCCGTACATCTTTGCCTTT CCACTCCACTCGAGTATGGTCTCGGGAGTC
- Glu2 ATATATGGATCCACCATGCAAAAGATTATGCATATTTC
- Glu3 TTAGGATCCACCATGGGGCAAAGCGTGCTCCGG CATGACTCTCTCGAGTAAAATGTCAGT ACTGACATTTTACTCGAGAGTCATG
- Glu4 TTAGGATCCACCATGAGGATTATTTGCAGGCAG AGTCAGCCCTTGAATTCGAACCTGCTTCAG CTGAAGCAGGTTCGAATTCAAGGGCTGACT GTCACTGGGCCCTTCCTTCCCATCCTCAGG CCTCAGGATGGGAAGGAAGGGCCCAGTGAC AATTCTAGATTATGGTAGGTCCGATGCAATGAC
- PCR was carried out for 30-40 cycles of amplification for 1 minute at 94°C, 1 minute at 50°C and 3 minutes at 72°C followed by 10 minutes at 72°C.
- Each amplified PCR product which was typically 0.8-1.1 kb in length was subcloned in the cloning vector pSKII+ (available from Stratagene) .
- cDNAs encoding the AMPA-selective receptors (Glul-Glu4) were assembled from three PCR fragments subcloned in pSKII+ in the mammalian expression vector Zem219b which carries an MT promoter, SV40 origin of replication and MTX marker. The vector is described in detail in Danish Patent Application No. 3023/88.
- nucleotide sequence of the entire coding region was determined by the dideoxy chain termination method of F. Sanger et al., Proc. Natl. Acad. Sci. USA 74. 1977, pp. 5463- 5467, using the double stranded plasmids as templates, a Sequenase kit (available from United States Biochemical) and sequence specific primers derived from the sequence shown by Keinanen et al, supra.
- BHK 570 cells were grown to 30-50% confluence in a tissue culture dish (Nunc #168381) in DMEM containing 1% penicillin/streptomycin (Gibco BRL #043-05070) . Prior to transfection, the cells were washed twice with calcium-free PBS after which 20 ml of DMEM was added to the cells.
- Transfection was carried out as described previously (product description: Lipofectin, Gibco BRL cat. No. 8292SA) . Briefly, 2 ⁇ g of the cDNA obtained in Example 3 was diluted in 300 ⁇ l of sterile water. 30 ⁇ g of Lipofectin (Gibco BRL) was diluted in 300 ⁇ l of sterile water. The cDNA and Lipofectin solutions were mixed and left at room temperature for 15 minutes. The Lipofectin/cDNA mixture was added dropwise to the cells while gently swirling the plates. The cells were then incubated for 16-24 hours, after which the medium was replaced with standard medium containing 1 nM methotrexate. Resistant colonies appearing after 1-2 weeks were isolated and propagated for further characterization.
- BHK 570 cells were grown at 37°C in 5% C0 2 in Costar ® 75 cm 2 vented culture flasks in a DMEM medium as described in Example 1. Prior to transfection,. the cells were transferred to Nunc 10 tissue culture dishes and grown to 60-80% confluence.
- 10 ⁇ g of the plasmid DNA obtained above was diluted to 250 ⁇ l in HBS (20 mM HEPES, pH 7.4, 150 mM NaCl) and mixed with 50 ⁇ l DOTMA liposomes (Boehringer Mannheim) diluted to 250 ⁇ l with HBS. The mixture and 8 ml medium were incubated with the cells overnight. The cells were diluted 50 fold and transferred to Nunc 15 cm tissue dishes in the same medium as described above to which 5 ⁇ M methotrexate had been added. Methotrexate resistant colonies appearing in 1-2 weeks were isolated with cloning rings and propagated for further characterization.
- BHK 570 cells obtained as described in Example 4 or 5 above were grown to 90-100% confluence in standard 15 cm tissue culture dishes (Nunc #168381) .
- the dishes were scraped and the cells were spun at 5000 x g for 10 minutes.
- the cell pellet was homogenized by means of an Ultra Turrax and centrifuged at 25000 x g for 10 minutes. This step was repeated twice.
- the final pellet was resuspended in 10 ml buffer and incubated at 37°C for 30 minutes and once more centrifuged at 25000 x g for 10 minutes.
- the pellet was resuspended in 10 ml buffer and frozen for 30 minutes on dry ice. After thawing, the suspension was centrifuged at 25000 x g for 10 minutes.
- the pellet was rehomogenised in buffer additionally containing 100 mM KSCN and used immediately in a binding assay. 500 ⁇ l of the homogenate was added to 25 ⁇ l 3 H-AMPA (final concentration 5 nM) and incubated for 30 minutes on ice.
- 500 ⁇ l of the homogenate was added to 25 ⁇ l 3 H-AMPA (final concentration 5 nM) and incubated for 30 minutes on ice.
- the pharmacological profile of BHK cell lines stably expressing glutamate receptors was investigated by the 3 H-AMPA binding assay described in Example 6.
- the profile of the Glul and Glu2 flip subunit stably expressed in BHK cells is shown in the following table.
- the Kd and Bmax values in these two cell lines were 12 nM and 0.6 pmol/mg membrane protein (Glul flip) and 20 nM and 6 pmol/ng membrane protein (Glu2 flip) .
- BHK 570 cells transfected with GluR subunits as described above, were grown on 35 mm plastic dishes (Falcon 3001) in DMEM (supplemented with 10% heat inactivated calf serum, antibiotics, non-essential amino acids, sodium pyruvate, and 5 ⁇ M methotrexate) .
- DMEM supplied with 10% heat inactivated calf serum, antibiotics, non-essential amino acids, sodium pyruvate, and 5 ⁇ M methotrexate
- cells were continuously perfused with mammalian Ringer (135 mM NaCl, 5.3 mM KC1, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 10 mM HEPES; pH 7.2) at 1 ml/min.
- Electrophysiological analysis of BHK 570 cells transfected with GluR cDNAs revealed the presence of ionic conductances activated by the neurotransmitter glutamic acid or its analogues.
- the conductances indicate the de novo synthesis and functional expression of glutamate receptor-ion channel complexes on the surface of the BHK cells.
- Fig. 1 shows sample traces obtained in one cell expressing GluR flip receptors. The magnitude of the response increases with increasing concentration of applied glutamate, indicating the activation of more receptors.
- Fig. 2 shows a log-dose response analysis of responses (such as those shown in the first figure) recorded in up to 12 cells.
- the responses have been normalized by dividing by the magnitude of the response to 30 ⁇ M glutamate.
- the error bars represent the standard error of the mean.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6500091A JPH07506970A (ja) | 1992-05-25 | 1993-05-19 | グルタミン酸レセプターを発現する細胞 |
EP93912656A EP0672135A1 (fr) | 1992-05-25 | 1993-05-19 | Cellule exprimant un recepteur de glutamate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK68592A DK68592D0 (da) | 1992-05-25 | 1992-05-25 | Celle |
DK685/92 | 1992-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993024629A1 true WO1993024629A1 (fr) | 1993-12-09 |
Family
ID=8096376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1993/000169 WO1993024629A1 (fr) | 1992-05-25 | 1993-05-19 | Cellule exprimant un recepteur de glutamate |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0672135A1 (fr) |
JP (1) | JPH07506970A (fr) |
DK (1) | DK68592D0 (fr) |
WO (1) | WO1993024629A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026401A1 (fr) * | 1994-03-29 | 1995-10-05 | Basf Aktiengesellschaft | Procede pour l'expression permanente de recepteurs du glutamate |
WO1998055870A1 (fr) * | 1997-06-04 | 1998-12-10 | A+ Science Invest Ab | Detection de molecules biologiquement actives a l'aide de capteurs biologiques pre-actives a base de cellule dans des systemes de separation a base de liquide |
US5849895A (en) * | 1993-04-20 | 1998-12-15 | Sibia Neurosciences, Inc. | Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor |
US6228610B1 (en) | 1993-09-20 | 2001-05-08 | Novartis Corporation | Human metabotropic glutamate receptor subtypes (hmR4, hmR6, hmR7) and related DNA compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991006648A1 (fr) * | 1989-10-27 | 1991-05-16 | The Salk Institute For Biological Studies | Compositions receptrices de glutamate, et procedes |
US5093525A (en) * | 1986-07-10 | 1992-03-03 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
-
1992
- 1992-05-25 DK DK68592A patent/DK68592D0/da not_active Application Discontinuation
-
1993
- 1993-05-19 JP JP6500091A patent/JPH07506970A/ja active Pending
- 1993-05-19 EP EP93912656A patent/EP0672135A1/fr not_active Withdrawn
- 1993-05-19 WO PCT/DK1993/000169 patent/WO1993024629A1/fr not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5093525A (en) * | 1986-07-10 | 1992-03-03 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
WO1991006648A1 (fr) * | 1989-10-27 | 1991-05-16 | The Salk Institute For Biological Studies | Compositions receptrices de glutamate, et procedes |
Non-Patent Citations (1)
Title |
---|
Science, Volume 249, August 1990, BERND SOMMER et al., "Flip and Flop: A Cell-Specific Functional Switch in Glutamate-Operated Channels of the CNS", page 1580 - page 1585. * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376660B1 (en) | 1993-04-20 | 2002-04-23 | Merck & Co., Inc. | Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor |
US6825322B2 (en) | 1993-04-20 | 2004-11-30 | Merck & Co., Inc. | Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor |
US5849895A (en) * | 1993-04-20 | 1998-12-15 | Sibia Neurosciences, Inc. | Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor |
US5985586A (en) * | 1993-04-20 | 1999-11-16 | Sibia Neurosciences, Inc. | Methods for identifying compounds that modulate the activity of human N-methyl-D-aspartate receptors |
US6033865A (en) * | 1993-04-20 | 2000-03-07 | Sibia Neurosciences, Inc. | Human n-methyl-d-aspartate receptor type 1 subunits, DNA encoding same and uses therefor |
US6111091A (en) * | 1993-04-20 | 2000-08-29 | Merck & Co., Inc. | Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefore |
US6956102B2 (en) | 1993-04-20 | 2005-10-18 | Merck & Co., Inc. | Human N-methyl-D-aspartate receptor subunits nucleic acids encoding same and uses therefor |
US6316611B1 (en) | 1993-04-20 | 2001-11-13 | Merck & Co., Inc. | Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor |
US6864358B2 (en) | 1993-04-20 | 2005-03-08 | Merck & Co., Inc. | Human n-methyl-d-aspartate receptor subunits, nucleic acids encoding same and uses therefor |
US6469142B1 (en) | 1993-04-20 | 2002-10-22 | Merck & Co., Inc. | Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor |
US6521413B1 (en) | 1993-04-20 | 2003-02-18 | Merck & Co., Inc. | Human N-methyl-D-aspartate receptor subnits, nucleic acids encoding same and uses therefor |
US6515107B2 (en) | 1993-09-20 | 2003-02-04 | Novartis Corporation | Human metabotropic glutamate receptor 7 subtypes |
US6228610B1 (en) | 1993-09-20 | 2001-05-08 | Novartis Corporation | Human metabotropic glutamate receptor subtypes (hmR4, hmR6, hmR7) and related DNA compounds |
US7253257B2 (en) | 1993-09-20 | 2007-08-07 | Novartis Corporation | Human metabotropic glutamate receptor subtype mGluR7b |
WO1995026401A1 (fr) * | 1994-03-29 | 1995-10-05 | Basf Aktiengesellschaft | Procede pour l'expression permanente de recepteurs du glutamate |
US6455303B1 (en) | 1997-06-04 | 2002-09-24 | Cellectricon Ab | Detection of biologically active molecules by use of pre-activated cell-based biosensors in liquid-based separation systems |
WO1998055870A1 (fr) * | 1997-06-04 | 1998-12-10 | A+ Science Invest Ab | Detection de molecules biologiquement actives a l'aide de capteurs biologiques pre-actives a base de cellule dans des systemes de separation a base de liquide |
Also Published As
Publication number | Publication date |
---|---|
JPH07506970A (ja) | 1995-08-03 |
DK68592D0 (da) | 1992-05-25 |
EP0672135A1 (fr) | 1995-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0708922B1 (fr) | Identification de ligands par amplification selective de cellules transfectees avec des recepteurs | |
Pauwels | Diverse signalling by 5-hydroxytryptamine (5-HT) receptors | |
Kuusinen et al. | Molecular dissection of the agonist binding site of an AMPA receptor. | |
US7491503B2 (en) | Identification of ligands by selective amplification of cells transfected with receptors | |
Tempia et al. | Fractional calcium current through neuronal AMPA-receptor channels with a low calcium permeability | |
US5807689A (en) | Methods for identifying compounds that modulate metabotropic glutamate receptor activity | |
JP2009050270A (ja) | ヒトニューロンニコチン性アセチルコリン受容体組成物及び該組成物を使用する方法 | |
EP0598840B1 (fr) | Compositions de canaux calciques humains et procedes | |
US6391566B1 (en) | Ionotropic human glutamate receptor subunit NR3 | |
WO1993024629A1 (fr) | Cellule exprimant un recepteur de glutamate | |
Tygesen et al. | The importance of two specific domains in ligand binding to the AMPA/kainate glutamate receptors GluR2 and GluR6 | |
EP0583917B1 (fr) | Récepteurs GLuR4 humains seliant à l'AMPA | |
JPH06181769A (ja) | Eaa1ファミリーのカイネート結合ヒトcns受容体 | |
JP3361554B2 (ja) | Eaa2ファミリーのカイネート結合ヒトcns受容体 | |
EP0674003A2 (fr) | Protèines modulatrices des récepteurs du système nerveux central humain | |
US5574144A (en) | Kainate-binding, human CNS receptors of the EAA4 family | |
JPH09511901A (ja) | グルタミン酸受容体(またはeaa受容体)ポリヌクレオチド及びその使用 | |
JP2003504012A (ja) | ホモメリックampa受容体及びヘテロメリックampa受容体 | |
JP2002045188A (ja) | ダイオキシンレセプター遺伝子およびその利用 | |
JP2001078782A (ja) | ダイオキシンレセプター遺伝子およびその利用 | |
JP2000354494A (ja) | ダイオキシンレセプター遺伝子およびその利用 | |
CA2463596A1 (fr) | Procede de criblage d'un inhibiteur de la mort cellulaire | |
JP2002543780A (ja) | 細胞及びアッセイ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1994 338555 Date of ref document: 19941207 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993912656 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993912656 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993912656 Country of ref document: EP |